Sutro Biopharma (NASDAQ:STRO) Receives "Neutral" Rating from Wedbush

Wedbush reiterated a "neutral" rating and set a $10.00 price objective (up previously from $2.00) on shares of Sutro Biopharma in a research report on Tuesday.